Elucida Oncology adds Dr. David Zaccardelli, Natalie McDonald and Gary Sender to its Board of Directors and announces Robert Essner stepping to Board Chairman

– USA, NJ –  Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, today announced the key additions of Dr. David Zaccardelli, Natalie McDonald, and Gary Sender to its Board of Directors.

“Each of the new directors bring substantial and successful experience, insights, and rigor to the Board, and I look forward to working alongside them as Elucida Oncology continues its advancement to a clinical-stage biotech company,” said Board Chairman, Robert Essner. “

The company also announced the transition of Robert Essner from Executive Chairman to Chairman of the Board of Directors

Robert Essner added: “I am also honored and excited to become Chairman of the Board. This transition from Executive Chairman has been made possible given the tremendous progress made over the past two years under Geno’s leadership as CEO and President, and the contributions of the highly talented team that he has assembled.”

“As our company has grown and matured, we have looked to expand the experience and capabilities of the Board, and we are thrilled to have attracted three proven industry leaders. Their vast and diverse experiences will help enormously in guiding the further development of our unique platform and help us reach our goals for improving the care of cancer patients,” said CEO Geno Germano.

About Dr. Zaccardelli

Dr. Zaccardelli has been President and CEO of Verona Pharma since February 2020. Previously, he served as President and CEO of Dova Pharmaceuticals from December 2018 until its acquisition by Sobi in November 2019. Dr. Zaccardelli was the Acting CEO of Cempra, Inc. from December 2016 until the company’s merger with Melinta Therapeutics, Inc., in November 2017. From 2004 until 2016, Dr. Zaccardelli served in several senior management roles at United Therapeutics Corporation, including COO, Chief Manufacturing Officer, and EVP, Pharmaceutical Development and Operations. Before joining United Therapeutics, he held various positions at Burroughs Wellcome & Co. and Bausch & Lomb Pharmaceuticals.

Dr. Zaccardelli received a Pharm.D. from the University of Michigan.

About Natalie McDonald

Natalie McDonald is President, CEO, and Founder of Create NYC, a global healthcare agency serving the pharmaceutical industry, which is now part of Ashfield Healthcare. Ms. McDonald conceived a new on-demand model pharmaceutical advertising agency and grew to Create NYC from a start-up company to a successful and highly competitive agency that was sold within 9 years. Before Create NYC, Ms. McDonald held progressively responsible roles in Advertising, Marketing, and Sales at Saatchi & Saatchi and Pfizer Inc.

She received her B.S.B.A. and B.S. in Chemistry from the University of Pittsburgh, and her M.B.A. from Drexel University.

About Gary Sender

Gary Sender was CFO of Nabriva Therapeutics plc, a publicly traded biopharmaceutical company, from 2016 until March 2021 when he retired from the company. Before Nabriva, Mr. Sender served as CFO and EVP at Synergy Pharmaceuticals from 2015 to 2016, and as SVP, Finance at Shire plc from 2009 until 2015 supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. He was also the founding CFO of Tengion, Inc., and spent 15 years in several leadership roles within Merck. He also serves on the board of directors of Harmony Biosciences Holdings Inc., Schrodinger Inc., and iBio Inc.

Mr. Sender received his B.S. from Boston University and an M.B.A. from Carnegie‑Mellon University.

About Elucida Oncology

Elucida Oncology, Inc., is a biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small C’Dot drug delivery platform. The company’s C’Dot-Drug-Conjugates, or CDCs, are novel therapeutics that can substantially increase the concentration of highly potent drugs in difficult-to-treat tumors with minimal systemic exposure due to their unique Target or Clear™ properties. CDCs enable precise tumor targeting and deep tumor penetration resulting in enhanced efficacy with reduced off-target toxicity, thereby addressing the limitations of antibody-drug-conjugates and more traditional drug carriers.

For more information: https://www.elucidaoncology.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team